Morphine Sulfate Oral Solution (硫酸吗啡口服溶液)硫酸吗啡口服溶液

This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。

Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。

生产企业Manufacturer

主要成分Active Ingredients

药物知识说明

吗啡是一种在国家药监局注册认定的药品。该药品含有吗啡-18270e9a等成分。

该药品关联的活性成分包括:吗啡morphine。这些成分信息来自国家药监局数据库。

该药品标注的生产企业为:东北制药集团沈阳第一制药有限公司Chinese legal name: 东北制药集团沈阳第一制药有限公司。

您可以探索含有相同成分的其他药品:吗啡-18270e9a成分药品。

本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。

Medicine Knowledge

morphine is a medicine registered with the national drug regulatory authority. It contains morphine as active ingredient(s).

Active ingredients associated with this product: morphinemorphine.

Manufacturers recorded for this product: 东北制药集团沈阳第一制药有限公司Chinese legal name: 东北制药集团沈阳第一制药有限公司.

Explore other medicines containing the same ingredient: morphine products.

Source: MedicineGraph authoritative database. Relationships derived from registered product information.

这是什么What is this

  • 通用名/品名Recorded product name: 硫酸吗啡口服溶液Morphine Sulfate Oral Solution (硫酸吗啡口服溶液)
  • 剂型Dosage form: 口服液剂Oral liquid
  • 规格Specification: 10ml:20mg10 mL:20 mg

本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.

主要成分Ingredients

生产企业Manufacturer

  • 东北制药集团沈阳第一制药有限公司Chinese legal name: 东北制药集团沈阳第一制药有限公司

注册信息NMPA approval number

  • 批准文号NMPA approval number: 国药准字H20080713

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.

  • 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
  • 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
  • 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.

本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.

English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.

NMPA approval number

国药准字H20080713

Manufacturer

Chinese legal name: 东北制药集团沈阳第一制药有限公司 (domestically manufactured)

Indications

English translation unavailable. The original Chinese source label remains available below.

Dosage and administration

English translation unavailable. The original Chinese source label remains available below.

Adverse reactions

English translation unavailable. The original Chinese source label remains available below.

Contraindications

English translation unavailable. The original Chinese source label remains available below.

Storage

English translation unavailable. The original Chinese source label remains available below.

Specification

English translation unavailable. The original Chinese source label remains available below.

中文说明书原文Original Chinese source label

批准文号

国药准字H20080713

生产企业

东北制药集团沈阳第一制药有限公司(国产)

适应症

硫酸吗啡口服溶液作为阿片受体激动剂,具有较强的镇痛、镇静作用,其临床适应症主要有各种晚期重度癌症疼痛、严重创伤、战伤、烧伤等疼痛,缓解心肌梗塞和左心室衰竭出现的心源性肺水肿。

用法用量

1.成人口服常用量为一次5~10mg,每4小时一次。 2.鉴于该产品起效快的特点,可以用作癌痛患者每日吗啡用药量的滴定和爆发性疼痛的补救给药,也可同控缓释吗啡制剂联合用药。

不良反应

主要有可能会出现恶心、呕吐、便秘等,在用药前及用药过程中采取适当预防和措施,能减轻或避免副作用发生。

禁忌

尚不明确。

贮藏

密封,置阴凉处。

规格

10ml:20mg

证据Evidence

  • 批准文号: 国药准字H20080713
  • rights: 本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.